Zacks: Brokerages Anticipate Colgate-Palmolive (NYSE:CL) Will Post Quarterly Sales of $3.98 Billion

Share on StockTwits

Equities research analysts expect Colgate-Palmolive (NYSE:CL) to report sales of $3.98 billion for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Colgate-Palmolive’s earnings, with the highest sales estimate coming in at $4.02 billion and the lowest estimate coming in at $3.93 billion. Colgate-Palmolive posted sales of $3.85 billion in the same quarter last year, which suggests a positive year-over-year growth rate of 3.4%. The business is expected to announce its next earnings results on Friday, October 25th.

According to Zacks, analysts expect that Colgate-Palmolive will report full year sales of $15.71 billion for the current year, with estimates ranging from $15.59 billion to $15.79 billion. For the next financial year, analysts expect that the company will post sales of $16.34 billion, with estimates ranging from $15.98 billion to $16.50 billion. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Colgate-Palmolive.

Colgate-Palmolive (NYSE:CL) last announced its earnings results on Friday, July 26th. The company reported $0.72 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.72. The company had revenue of $3.87 billion for the quarter, compared to analyst estimates of $3.88 billion. Colgate-Palmolive had a negative return on equity of 10,821.98% and a net margin of 14.77%. Colgate-Palmolive’s revenue for the quarter was down .5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.77 earnings per share.

CL has been the topic of a number of research analyst reports. Macquarie lifted their price target on Colgate-Palmolive from $65.00 to $72.00 and gave the company a “neutral” rating in a report on Monday, April 29th. Wells Fargo & Co lifted their price target on Colgate-Palmolive from $68.00 to $70.00 and gave the company a “market perform” rating in a report on Monday, July 29th. UBS Group lifted their price target on Colgate-Palmolive from $80.00 to $82.00 and gave the company a “buy” rating in a report on Monday, July 29th. Bank of America set a $80.00 price target on Colgate-Palmolive and gave the company a “buy” rating in a report on Friday, July 12th. Finally, Morgan Stanley lifted their price target on Colgate-Palmolive from $72.00 to $74.00 and gave the company an “equal weight” rating in a report on Monday, July 29th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and six have assigned a buy rating to the stock. Colgate-Palmolive currently has a consensus rating of “Hold” and an average price target of $73.87.

Shares of CL stock opened at $72.61 on Monday. Colgate-Palmolive has a 1-year low of $57.41 and a 1-year high of $76.41. The company has a current ratio of 1.13, a quick ratio of 0.78 and a debt-to-equity ratio of 32.25. The company has a market capitalization of $62.70 billion, a price-to-earnings ratio of 24.45, a P/E/G ratio of 4.70 and a beta of 0.76. The stock’s fifty day simple moving average is $72.60 and its 200-day simple moving average is $70.03.

The company also recently announced a quarterly dividend, which was paid on Thursday, August 15th. Shareholders of record on Thursday, July 18th were paid a $0.43 dividend. The ex-dividend date was Wednesday, July 17th. This represents a $1.72 dividend on an annualized basis and a yield of 2.37%. Colgate-Palmolive’s dividend payout ratio (DPR) is currently 57.91%.

In other Colgate-Palmolive news, insider Prabha Parameswaran sold 5,000 shares of the business’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $69.35, for a total value of $346,750.00. Following the transaction, the insider now owns 20,893 shares in the company, valued at $1,448,929.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ian M. Cook sold 19,500 shares of the business’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $74.19, for a total value of $1,446,705.00. Following the completion of the transaction, the insider now owns 1,127,542 shares in the company, valued at approximately $83,652,340.98. The disclosure for this sale can be found here. Insiders sold 564,285 shares of company stock worth $40,530,290 in the last 90 days. Corporate insiders own 1.14% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of CL. Krane Funds Advisors LLC bought a new stake in shares of Colgate-Palmolive during the 2nd quarter worth about $25,000. Meridian Wealth Management LLC bought a new stake in shares of Colgate-Palmolive during the 1st quarter worth about $29,000. Lipe & Dalton bought a new stake in shares of Colgate-Palmolive during the 2nd quarter worth about $29,000. Enterprise Trust & Investment Co bought a new stake in shares of Colgate-Palmolive during the 2nd quarter worth about $36,000. Finally, Princeton Global Asset Management LLC bought a new stake in shares of Colgate-Palmolive during the 1st quarter worth about $43,000. Hedge funds and other institutional investors own 75.83% of the company’s stock.

About Colgate-Palmolive

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. It offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; and personal care products, such as liquid hand soaps, bar soaps, shower gels, deodorants and antiperspirants, skin care products, and shampoos and conditioners.

Further Reading: What Are Cryptocurrencies?

Get a free copy of the Zacks research report on Colgate-Palmolive (CL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.